Compare ADMA Biologics Inc (ADMA) vs Firy Inc. (FIRY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Firy Inc. — how do they compare? ADMA Biologics Inc trades at $9.18 (market cap $2.13B), while Firy Inc. trades at $9.3 (market cap $143.59M). The key difference: ADMA Biologics Inc is far larger — about 14.8× Firy Inc.'s market cap, and Firy Inc. is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | FIRY | |
|---|---|---|
Market Cap | $2.13B | $143.59M |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $12.45 |
52-Week Low | $7.60 | $2.28 |
Enterprise Value | $2.20B | $87.26M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
FIRY, formerly Skillz Inc., trades at $9.20, down 5.54% today, amid a recent rebranding and mixed quarterly results. The stock shows a bullish technical signal with strong moving average support, while fundamentals reveal persistent losses despite a high gross margin of 87.75%. Revenue has declined from $270M in 2022 to $104M in 2025, with net income margins deeply negative. Cash flow remains negative, though operating losses have narrowed from 2022 peaks.
Outlook is cautious; the company's cost structure and profitability challenges pose significant risks, offset by potential from legal victories and strategic shifts. Analysts are mostly neutral, with 60% hold ratings. Investors should weigh the high execution risk against any turnaround prospects in the competitive mobile gaming sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Firy Inc.
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →
